Cargando…

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination

BACKGROUND: Breakthrough infections after SARS-CoV-2 vaccination have been reported. Clinical outcomes in these persons are not widely known. METHODS: We evaluated all vaccinated persons with breakthrough infection ≥14 days after the second vaccine dose and unvaccinated controls matched on age, sex,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butt, Adeel A., Nafady-Hego, Hanaa, Chemaitelly, Hiam, Abou-Samra, Abdul-Badi, Khal, Abdullatif Al, Coyle, Peter V., Kanaani, Zeina Al, Kaleeckal, Anvar H., Latif, Ali Nizar, Masalmani, Yousuf Al, Bertollini, Roberto, Raddad, Laith J. Abu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349447/ https://www.ncbi.nlm.nih.gov/pubmed/34375762 http://dx.doi.org/10.1016/j.ijid.2021.08.008

Ejemplares similares

All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
por: AlNuaimi, Asma A, et al.
Publicado: (2023)

COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar
por: Butt, Adeel A, et al.
Publicado: (2022)

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers
por: Alishaq, Moza, et al.
Publicado: (2021)

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
por: Ayoub, Houssein H, et al.
Publicado: (2021)

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
por: Seedat, Shaheen, et al.
Publicado: (2021)

COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
por: Tayar, Elias, et al.
Publicado: (2023)

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020
por: Al Kuwari, Hanan M, et al.
Publicado: (2020)

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
por: Jeremijenko, Andrew, et al.
Publicado: (2021)

2273. Azithromycin Use Before and During COVID- 19 and Impact of Implementing Evidence-based Guidelines
por: Shams, Sherin, et al.
Publicado: (2023)

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
por: Abu-Raddad, Laith J, et al.
Publicado: (2020)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience
por: Bsat, Raghid, et al.
Publicado: (2022)

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
por: Mahmoud, Mai A., et al.
Publicado: (2023)

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

History of primary-series and booster vaccination and protection against Omicron reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
por: Altarawneh, Heba N., et al.
Publicado: (2023)

Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
por: Qassim, Suelen H., et al.
Publicado: (2023)

Duration of immune protection of SARS-CoV-2 natural infection against reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
por: Nasrallah, Gheyath K., et al.
Publicado: (2021)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections.
por: Altarawneh, Heba N, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qvlvta4p9vqsg8c53ekp4q4juh